Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)

Market Cap	14.55B +107.1%
Revenue (ttm)	624.52M +268.6%
Net Income	-947.49M
EPS	-2.37
Shares Out	399.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,897,885
Average Volume	6,275,255
Open	36.75
Previous Close	36.69
Day's Range	36.40 - 37.55
52-Week Range	15.89 - 63.59
Beta	0.95
RSI	40.30
Earnings Date	Mar 25, 2026

About SHA:688062

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; and JUNMAIKANG, an autoimmune Adalimumab injection. Its oncology product pipeline includes 9MW2821, a Nectin-4 t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 1,362
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688062

Financial Performance

In 2024, SHA:688062's revenue was 199.78 million, an increase of 56.28% compared to the previous year's 127.84 million. Losses were -1.04 billion, -0.90% less than in 2023.